Koninklijke Philips (NYSE:PHG) Stock

Koninklijke Philips

Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (around 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal care products.

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips NV

Phil-Good Products Inc

BiomX Inc

BiomX Inc Warrants (13/12/2023)

PETS AT HOME GRP UNSP/ADR by Pets at Home Group PLC

Pets at Home Group PLC

PHARMING GROUP NV ORD by Pharming Group NV

Pharming Group

News

Philips Announces 2024 Dividend Exchange Ratio Of One New Common Share For Every 23.6353 Existing Common Shares

Buybacks

Royal Philips Announced That It Will Repurchase Up To 6M Shares To Cover Certain Of Its Obligations Arising From Its Long-term Incentive Plans Representing An Amount Of Up To Approximately EUR 125M

Royal Philips And March Of Dimes Announced A Collaboration Aimed At Improving Maternal Health Education Through The Philips Avent Pregnancy+ App

President Donald Trump&#8217;s threat to impose a sweeping 50% tariff on all European Union imports starting June 1 sparked a broad selloff across European markets Friday, triggering fears of a transatlantic trade war just as global <a href="https://www.benzinga.com/topic/tariffs">growth faces renewed pressure.</a>
In a post on Truth Social, Trump said the EU&#8217;s "powerful Trade Barriers, VAT Taxes, ridiculous Corporate Penalties, Non-Monetary Trade Barriers, Monetary Manipulations, unfair and unjustified lawsuits against American Companies" were to blame for an annual trade deficit exceeding $250 billion, which he called "totally unacceptable."
The proposed tariff would exempt goods manufactured in the United States, potentially creating sharp distortions for EU-based exporters and global supply chains.
<h3 class="wp-block-heading">European Benchmarks Tumble</h3>
The fallout was immediate in markets. The Euro STOXX 50 index – as closely tracked by the iShares MSCI Eurozone ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EZU#NYSE">EZU</a>) – dropped 3%, Italy's FTSE MIB sank 2.9%, France's CAC 40 lost 2.6% and Spain's IBEX 35 fell 2.2%. 
Germany's DAX, as tracked by the iShares MSCI Germany Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWG#NYSE">EWG</a>), which is home to many export-heavy firms, slid 2.3%.
Financial stocks bore the brunt of the decline, with Deutsche Bank AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) falling 6.1%, Société Générale SA (OTCPK: SCGLY) down 5.3% and Banco Bilbao Vizcaya Argentaria SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBVA#NYSE">BBVA</a>) sliding 5%.
 Industrial and luxury exporters also came under heavy pressure, including Bayerische Motoren Werke AG (OTCPK: BMWYY), or BMW (−4.5%), UniCredit SpA (OTCPK: UNCRY) (−4.5%) and EssilorLuxottica SA (OTCPK: ESLOY) (−4.2%).
<h3 class="wp-block-heading">Export Exposure To US Trade Is Key</h3>
The tariff threat has placed a spotlight on European companies heavily reliant on U.S. revenues.
In Germany, Adidas AG (OTCPK: ADDYY) derives roughly a third of its revenue from the United States, while SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) generates about 40% of its turnover from North America. 
Chipmaker Infineon Technologies AG (OTCPK: IFNNY) is also significantly exposed due to its automotive and electronics customers.
French luxury and tech firms are equally at risk. LVMH Moët Hennessy Louis Vuitton SE (OTCPK: LVMUY) earns close to 25% of its revenue in the U.S., while Dassault Systèmes SE (OTCPK: DASTY) has a strong footprint in North American enterprise software. Hermès International SA (OTCPK: HESAY) pulls about 20-25% of its sales from the American market.
Italian brands like Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>), with over 30% of sales from the U.S., and EssilorLuxottica SA (OTCPK: ESLOY), which owns Oakley and Ray-Ban, are also vulnerable. 
In the Netherlands, tech heavyweight ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) earns about 20-25% of revenue from the U.S., and Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) maintains a major healthcare business across North America.
<h3 class="wp-block-heading">EU Retaliation Risk Grows For US Stocks</h3>
For U.S. corporations with heavy exposure to Europe—particularly in tech, autos, agriculture and aviation—the economic consequences could be significant if the European Union responds in kind.
The 2018 EU countermeasures to Trump&#8217;s steel tariffs included duties on motorcycles, bourbon and orange juice—strategic hits on U.S. swing-state exports.
EU officials may also revisit tech taxation disputes, where U.S. firms like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) are already under regulatory scrutiny.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45584696/trump-threatens-tim-cook-to-manufacture-iphones-in-the-us-or-face-at-least-25-tariffs">Trump Threatens Tim Cook To Manufacture iPhones In US Or Face &#8216;At Least 25%&#8217; Tariffs: AAPL Stock Slides Over 3% In Premarket </a></li>
</ul>
Photo Courtesy: Joshua Sukoff On Shutterstock.com

Analyst Color

Macro Economic Events

Sector ETFs

Eurozone

Econ #s

Economics

Analyst Ratings

ETFs

AAPL

ADDYY

ASML

BBVA

BMWYY

DASTY

ESLOY

GOOGL

HESAY

IFNNY

LVMUY

MSFT

RACE

SCGLY

UNCRY

Trump Tariff Threat Hits Europe: Stocks Sink As 50% Duties Loom

General

Philips Launches RADIQAL Trial To Generate Evidence For Ultra-Low X-Ray Dose Technology For Coronary Procedures

<a href="https://www.globenewswire.com/Tracker?data=95ttCcrFviRqrRp3UsJTOWq67jNPTSKrVo1T8y4V65E_XLeHk__aAnyrGHzuO5kcM2MndMWx2QPViGsNwnaqvpO9LgQHVoNIPZSjyk3BOYY=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA))), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United States, VeriSight Pro brings real-time 3D imaging directly inside the heart, helping physicians perform procedures with greater clarity — without the need for general anesthesia. Designed for procedures such as transcatheter valve repair and left atrial appendage closure, VeriSight Pro offers high-resolution 2D and 3D visualization directly within the heart chambers. This enables confident clinical decision-making in structural heart and electrophysiology interventions, while removing the need for general anesthesia and associated risks.

Philips Launches 3D Heart Imaging Catheter In Europe to Boost Precision, Cut Anesthesia Use

<a href="https://www.globenewswire.com/Tracker?data=V4p4HYBM4nfxb1-5UUB4gwuVm1ELD_1w6CHJ2OD-rFyA3NnWD0ESScEwDhI8H3pYC1W5FHu4ztfw4W2hqu3X9BDI3ETCBMgB-EPmUnLbHU0=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA))), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the "Notes") under its European Medium Term Note (EMTN) program.
The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined in <a href="https://www.globenewswire.com/Tracker?data=27zD7zL8K-bIGWXu-UdjhCRFTCuh5XEkUKbt1JfV5_BJfjnxuUfdsHRzIsPVF_dIj7GaisBoYSapOB_Rl3sLEXQ5oLTSsVSnwirMvx_Kd18LKZ9zrkPEK35i7dn8NFPkDMXy0M_cAQshhp3FPsAhNXQ6SOHXBsqXwowEeqoN4-ZEso6f-YiSYS-GWJCC4yD_0taQaZIf7ujVV_yXoWVKlg==">Philips' Sustainable Finance Framework</a>.
The issue price for the Notes due 2030 is 99.859% with a Coupon of 3.250%, resulting in a yield of 3.281% and the issue price for the Notes due 2035 is 99.595% with a Coupon of 4.000%, resulting in a yield of 4.050%. The 5 and 10 year tranches were oversubscribed by more than 3 and 4 times, respectively.

Royal Philips Prices Offering Of EUR 500M Fixed Rate Notes Due 2030 And EUR 500M Fixed Rate Notes Due 2035 Under EMTN Program

Google Cloud helps streamline marketing processes, enhancing brand consistency and reducing operational costs

GOOG

Google Cloud And Philips Partner To Transform Global Marketing With AI-Powered Digital Asset Management

<a href="https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.">https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.</a>
&nbsp;
From cutting scan times, to speeding workflow and improving image quality, Philips is already empowering healthcare providers with AI-powered solutions to deliver faster, more accurate diagnoses for their patients [1]. Today at a major industry gathering <a href="https://www.usa.philips.com/healthcare/event/upcoming/ismrm-2025">ISMRM</a>, the company announced a new breakthrough collaboration with NVIDIA to harness cutting-edge advances in AI for MR imaging.
 &nbsp;

NVDA

Reported Earlier: 'Philips Collaborates With NVIDIA To Improve Patient Care In MR With Latest AI Advances' - Phillips

Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) reported first-quarter 2025 adjusted earnings per share of 26 cents (or 0.25 euros), beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 20 cents</a>.
The Dutch healthcare technology group reported quarterly sales of $4.31 billion (4.09 billion euros), beating the consensus of $4.10 billion.
Comparable <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45213459/philips-delivers-on-q1-results-with-ongoing-order-intake-growth" rel="noreferrer noopener">sales decreased</a> by 2%, including a double-digit decline in China.
<ul>
<li>Diagnosis &amp; Treatment comparable sales decreased by 4%, due to a double-digit decline in China and on the back of a high comparison base in prior years. Adjusted EBITA margin improved, driven by productivity measures, mix effects, and innovation, partly offset by lower fixed cost absorption due to lower sales.</li>
<li>Connected Care comparable sales were broadly flat across businesses, and the Adjusted EBITA margin was 3.5%, mainly due to an unfavorable mix and cost phasing, partly offset by productivity measures and innovation.</li>
<li>Personal Health comparable sales increased 1%. A double-digit decline in China largely offset high-single-digit growth. The adjusted EBITA margin remained in line with last year&#8217;s.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45147390/ge-healthcares-strong-q1-took-back-seat-to-tariffs-analyst-sees-2026-tariff-impact-less-than-2025" rel="noreferrer noopener">GE HealthCare&#8217;s Strong Q1 Took Back Seat To Tariffs, Analyst Sees 2026 Tariff Impact Less Than 2025</a>
&#8220;Our order intake growth continued with strong momentum, particularly in the US, coupled with positive growth in personal health, providing an encouraging start to the year,&#8221; said Roy Jakobs, CEO of Royal Philips.
&#8220;In an uncertain macro environment that has intensified due to the potential impact of tariffs, we are focused on what we can control. We are improving our supply chain agility, taking decisive cost actions to mitigate financial impact where possible, and ensuring we can continue to serve our customers and consumers,&#8221; Jakobs added.
Adjusted EBITA margin decreased 80 basis points to 8.6%, mainly due to the decline in sales, partly offset by higher gross margins from innovations and productivity measures.
Income from operations increased to 154 million. Free cash flow was an outflow of 1.09 billion, mainly due to the 1.025 billion payment relating to the Philips Respironics recall-related medical monitoring and personal injury settlements in the U.S.
Guidance:&nbsp;In an uncertain macro environment, Philips&#8217; outlook for the full year 2025 is updated to include the assumed impact of currently announced tariffs, including current bilateral US-China and rest of world tariffs, and the resumption of the paused U.S. tariffs on July 9. It excludes the potential wider economic impact.
2025 comparable sales growth of <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43817640/philips-stock-falls-as-china-weakness-drags-q4-earnings-2025-outlook" rel="noreferrer noopener">1%—3% remains unchanged</a>.
Adjusted EBITA margin range to be 10.8%-11.3% (compared to 11.8%-12.3% previously), including an estimated net tariff impact of 250-300 million euros after substantial tariff mitigations.
The company anticipates that 2025 performance will be skewed toward the latter part of the year, with Q2 showing modest improvement from Q1.
Philips is on track to deliver savings of 800 million euros in 2025.
Price Action: PHG stock is down 4.76% to $24.42&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45210400/ahead-of-uber-earnings-analyst-raises-forecast" target="_blank" rel="noreferrer noopener">Ahead Of Uber Earnings, Analyst Raises Forecast</a></li>
</ul>
Photo by Mats Wiklund via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

Lower Demand In China Disrupts Philips Q1 Sales, Cuts 2025 Profitability Target On Potential Tariff Impact

WIIM

Koninklijke Philips shares are trading lower after the company reported Q1 financial results and trimmed its adjusted EBITA margin. Also, the company reported a year-over-year decrease in comparable sales.

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Outlook&nbsp;
In an uncertain macro environment, Philips' outlook for full year 2025 is updated to include the assumed impact of currently announced tariffs. This includes current bilateral US-China and rest of world tariffs, the resumption of the paused US tariffs on July 9 and excludes potential wider economic impact.
&nbsp;• Philips' outlook for comparable sales growth remains unchanged at 1%-3%
&nbsp;• Adjusted EBITA margin range to be 10.8%-11.3%, including an estimated net tariff impact of EUR 250-300 million after substantial tariff mitigations, a 100 bps reduction versus previous outlook, based on the above-referenced assumptions
&nbsp;• As a result, free cash flow to be slightly positive for the full year, after the payout of EUR 1,025 million Philips Respironics recall-related medical monitoring and personal injury settlements in the US
&nbsp;• The company continues to anticipate 2025 performance will be skewed toward the latter part of the year, with Q2 showing modest improvement from Q1

Koninklijke Philips Holds 2025 Sales Growth Outlook At 1–3%; Trims Adjusted EBITA Margin To 10.8%-11.3%, Down 100 Bps From Prior On €250–300M Tariff Hit

Koninklijke Philips Comparable Sales Fell 2% YoY, With China Down Double Digits; Personal Health Rose 1%, But Diagnosis & Treatment Dropped 4%

Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.20 by 31 percent. This is a 6.43 percent decrease over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $4.31 billion which beat the analyst consensus estimate of $4.10 billion by 5.16 percent. This is a 4.14 percent decrease over sales of $4.49 billion the same period last year.

Earnings Beats

Koninklijke Philips Q1 Adj. EPS $0.26 Beats $0.20 Estimate, Sales $4.31B Beat $4.10B Estimate

<ul>
<li>Philips integrates advanced AI algorithms into its MRI systems, featuring Dual AI-driven engines in SmartSpeed Precise [1] to enable faster scanning</li>
<li>Innovations include the latest AI-enabled MR Workspace software to enhance patient throughput, reduce scan times, and improve image quality—leading to more accurate diagnoses, shorter wait times, and reduced backlogs for MRI scans</li>
<li>The latest technology is available across Philips' 1.5T and 3.0T MRI scanners [2], including the latest helium-free 1.5T high-performance BlueSeal wide-bore system [3,4], supporting healthcare providers worldwide</li>
</ul>
Amsterdam, The Netherlands and Vienna, Austria – <a href="https://www.globenewswire.com/Tracker?data=OKgd3pahs2OQXp2t4hkPVLl1U9rIS3SmOHkk6tyZsuLb8QFojiM4ij8_4XeGxDBlZbDWXNKTXLOUJc6NoVc3tMxnGuc5c_t9lXPMIJcbK4M=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA))), a global leader in health technology, strengthens its MRI leadership with the launch of SmartSpeed Precise [1], powered by Dual-AI engines. Building on its award-winning [5] <a href="https://www.globenewswire.com/Tracker?data=IMPR-tHgOkNuf-q0b2iHzk38Vi3ewcMDTGkWtvtbSu79bOKVz-WOQlFgsmNaTpM80EZAq0drWfE0tqmDdqVCkJ3zNe9fZ92kSsGod3LGto9pBSSWldZ0RgCy3J-1MIlVY-ZbbYWpb4Oml7EJv-AeX81ohdFHVvdh-CUzt7qUSt7r-TozfvUBurefi0Qkkb_n">Compressed SENSE</a> and <a href="https://www.globenewswire.com/Tracker?data=65mXpke_iCjhmJhIaDGs3Bc-xo0_Ro_8mGPrEx6pWWW0KqYdUYjhy5gfdokUT3bWxu8BRhlnfQJbPMKxAaVi0Fei7rmQZaznwbC1AcH5mtUKCOIIJTX7d1hiETvsmVvzwCiZ5MWoR6zFY9xk-fvIzg==">SmartSpeed</a> technologies, this next-generation solution delivers faster scans with higher image quality. Debuting at the 2025 European Congress of Radiology (<a href="https://www.globenewswire.com/Tracker?data=sZzAy5ub4MbOdn7i70QxsPn8g9m6dkV1-4oqa0AbOWtt_46N-cOdZXW43vjSQFP1MgwvDEpv6SnX_py3NGZGG-uEvl_p50iZ-d5G3lTEDH0=">ECR 2025</a>, Feb. 26-Mar. 2, Vienna, Austria), SmartSpeed Precise significantly improves scan speed and diagnostic image quality, extending AI-driven efficiency across the entire <a href="https://www.globenewswire.com/Tracker?data=y3CI4tgtz6u9YhKgvbCYmA8ErlMo7FbBbbqQjm_tUWJgyke2WspHRo1o7ARm42K9NrpO7bwViqGGXRQoJLFRV4sU3M_i7eY6iF4sPymA-CS-RKr3uCTdhJ3GH1Gxle30eyUtf6qyYNRqSLt5WGe5Dw==">Philips MR portfolio</a>—including existing customer systems. Also showcased will be the latest MR Workspace software release 12 [6], which streamlines workflows and empowering clinicians to deliver faster, more accurate diagnoses. These innovations reflect Philips' commitment to enhancing efficiency, accessibility, and precision in MR imaging. &nbsp;

Biotech

Philips Integrates Advanced AI Into MRI Systems With Dual AI Engines For Faster Scanning, Enhanced Image Quality, And Reduced Wait Times; Innovations Include Helium-Free 1.5T BlueSeal Wide-Bore System

Integrating advanced data analytics into clinical practice to improve patient care

Philips And Mass General Brigham Collaborate To Unify Medical Data With AI For Smarter Clinical Decisions

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst James Heaney upgraded the rating for Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Underperform to Hold and raised the price target from $55 to $100. Roku shares closed at $92.41 on Wednesday. <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Lofting upgraded the rating for BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from Underweight to Neutral. BP shares closed at $34.54 on Wednesday. <a href="https://www.benzinga.com/quote/BP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Christopher Danely upgraded NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) from Neutral to Buy and raised the price target from $210 to $290. NXP Semiconductors shares closed at $245.58 on Wednesday. <a href="https://www.benzinga.com/quote/NXPI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Graham Doyle upgraded Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) from Neutral to Buy. Philips shares closed at $25.05 on Wednesday. <a href="https://www.benzinga.com/quote/PHG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna analyst Mehdi Hosseini upgraded Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) from Neutral to Positive and raised the price target from $75 to $125. Lam Research shares closed at $87.66 on Wednesday. <a href="https://www.benzinga.com/quote/LRCX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20144731/image-172-1024x524.png" alt="" class="wp-image-791761" style="width:587px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20144731/image-172-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20144731/image-172-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20144731/image-172-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/20144731/image-172.png 1285w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Upgrades

Price Target

Markets

LRCX

NXPI

ROKU

This BP Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Thursday

UBS analyst Graham Doyle upgrades Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) from Neutral to Buy.

UBS Upgrades Koninklijke Philips to Buy

Dutch healthcare technology group&nbsp;Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock is trading lower on Wednesday after the fourth quarter <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43805254/philips-delivers-growth-improved-profitability-and-strong-cash-flow-in-q4-and-2024-continues-solid" rel="noreferrer noopener">earnings missed expectations</a>.
Philips&nbsp;reported fourth-quarter sales of 5.04 billion euros (around $5.26 billion), slightly higher than 5.0 billion euros a year ago, missing the consensus of 5.10 billion euros.
The company reported adjusted EPS of 51 cents, up from 40 cents a year ago, but it missed the consensus of 57 cents.
Comparable order intake increased 2% in the quarter, with strong performance in the North America and Growth geographies, partly offset by a double-digit decline in demand in China.
Group comparable sales increased 1% in the quarter, with a growth of 5% in the rest of the world, largely offset by a double-digit decline in China, where market conditions are expected to remain uncertain. For the full year, comparable order intake and sales increased 1%, up 4% excluding China (within management <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41570381/dutch-health-tech-firm-philips-q3-earnings-miss-expectations-lowers-annual-forecasts-on-weak-demand" rel="noreferrer noopener">guidance of 0.5%-1.5%</a>).
Diagnosis &amp; Treatment&nbsp;and Personal Health&nbsp;comparable sales decreased 1% and 2%, respectively, in the quarter due to a double-digit decline in China.
The fourth-quarter net loss was 334 million euros, compared with a profit of 39 million euros a year ago. The loss mainly reflects a tax charge of 449 million euros against a credit of 132 million euros.
Adjusted EBITA was 679 million euros compared with 653 million euros, while its adjusted EBITA margin was 13.5%.
Guidance: Philips expects 2025 comparable sales growth of 1%—3%, including a mid-to-high single-digit decline in China. The company forecasts that the adjusted EBITA margin will increase 30-80 bps to 11.8%—12.3%.
The Dutch medical technology company anticipates comparable sales growth to be back-end-loaded in the year, with a mid-single-digit decline in Q1 mainly due to lower demand in China and royalties phasing, with correspondingly lower Adjusted EBITA margin.
Philips is raising its productivity savings target for the 2023-2025 period from 2 billion euros to 2.5 billion euros, driven by cost efficiencies and further simplification of its operating model. 800 million euros will be delivered in 2025.
Philips has also provided guidance on free cash flow post-settlements, expecting between 400-600 million euros in 2025.
Price Action: PHG stock is down 11.6% at $25.03 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43794325/jp-morgans-acquisition-of-student-loan-start-up-falls-out-founder-in-court-for-alleged-fraud-ceo-jamie-dimon-calls-it-a-huge-mistake" target="_blank" rel="noreferrer noopener">JPMorgan, Charlie Javice Case Takes Center Stage In Court This Week: Report</a></li>
</ul>
Photo by Mats Wiklund via Shutterstock

Philips Stock Falls As China Weakness Drags Q4 Earnings, 2025 Outlook

Press Releases

Google Cloud and Philips Collaborate to Drive Consumer Marketing Innovation and Transform Digital Asset Management with AI

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now

Philips Future Health Index 2025 Report Highlights Significant Trust Gap in Healthcare AI Between Clinicians and Patients

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures

Philips and March of Dimes Bring Maternal and Pregnancy Health Content to Philips Avent Pregnancy+ App

Philips to repurchase up to 6 million shares to cover long-term incentive plans

Philips announces exchange ratio for 2024 dividend

Philips Foundation 2024 Annual Report: expanding access to quality healthcare for 46.5 million people

Comments

Koninklijke Philips

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL